NCT03554174
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 18 versions: 16 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 11 words
- Study completion pushed from Sep 2026 to Dec 2026
- Secondary endpoints: details revised at 2 of 3 entries
- Minor Study completion date: Sep 2025 to Sep 2026v17
- Minor Study completion date: Jun 2025 to Sep 2025v16
- Minor Study completion date: Apr 2025 to Jun 2025v15
- Minor Primary completion date changed from estimate of Feb 27, 2024 to Jul 8, 2021
- Study completion date: Apr 2024 to Apr 2025
Show 10 earlier versionsHide 10 earlier versions
- Notable Primary completion date: Feb 27, 2023 to Feb 27, 2024
- Study completion date: Apr 2023 to Apr 2024
- Notable Primary completion date: Jun 2022 to Feb 27, 2023
- Start date: Jun 30, 2018 to Feb 27, 2018
- Secondary endpoints: 7 to 3
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised
- Notable Primary completion date: Jun 2021 to Jun 2022
- Site contact updated
- Minor Primary completion date: Apr 2021 to Jun 2021v9
- Minor Site contact updatedv7
- Minor Site contact updatedv6
- Minor Site contact updatedv4
- Minor Site contact updatedv3
- Minor Start date changed from estimate of Jun 2018 to Jun 30, 2018v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Changes in electrical brain activity associated with neuroplasticity measured by Electroencephalography (EEG)
Timeframe: One day and two weeks after each experimental session
Secondary (3)
Changes in verbal memory [ Time Frame: One day and two weeks after each experimental session ]
Change in mood symptoms using the GRID-Hamilton Depression Rating Scale (GRID-HAM-D)
Change in mood symptoms using the Quick Inventory of Depressive Symptoms (QIDS-SR16)
Arms and interventions
Placebo/Low Dose PsilocybinExperimental
Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
Placebo/Medium Dose PsilocybinExperimental
Subjects in this arm receive placebo in the first session and medium dose psilocybin in the second session.
Low Dose Psilocybin/PlaceboExperimental
Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
Medium Dose Psilocybin/PlaceboExperimental
Subjects in this arm receive medium dose psilocybin in the first session and placebo in the second session.
Drugs: Low Dose Psilocybin, Placebo, Medium Dose Psilocybin
Sites
1 site in 1 country
- VA Connecticut Healthcare System, West Haven CampusWest Haven, Connecticut, United States